{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:26:41Z","timestamp":1790022401864,"version":"4.0.1"},"reference-count":28,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: This study aimed to assess the prevalence of colistin prescriptions among patients with multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) infections admitted to a tertiary teaching hospital in Jordan. Additionally, the study evaluated the appropriateness of colistin prescriptions and assessed resistance levels of this strain. Materials and Methods: In this retrospective study, adult patients who were infected with MDR\u00a0P. aeruginosa and were admitted to Jordan University Hospital between January 2018 and March 2024 were included. Data on demographics, clinical characteristics, sources of infection, antibiotic therapy, and clinical outcomes were collected. Results: Out of the 85 patients who met the inclusion criteria for having MDR P. aeruginosa, colistin was administered to 16 patients (18.8%). Notably, approximately two-thirds (68.7%) of the isolates from patients who received colistin were classified as extensively drug-resistant (XDR). Among the isolates, 15 out of 16 (93.8%) were resistant to both ciprofloxacin and imipenem. Among the patients requiring colistin, five (31.3%) discontinued therapy, while two (12.5%) remained on colistin despite the availability of safer alternatives. No significant difference was observed in 30-day all-cause mortality between patients treated with colistin (0%) and those who were not (4.3%, p = 1.00). Similarly, the incidence of acute kidney injury did not differ significantly between the colistin group (0%) and the non-colistin group (p = 1.00). No significant difference was found in the hospital stay between colistin-treated patients (median 10.5 days, IQR [5.0\u201314.0]) and those not treated with colistin (median 13.0 days, IQR [7.0\u201321.0]), (p = 0.22). Conclusions: This study demonstrated that colistin was selectively initiated in high-risk patients, particularly those with XDR P. aeruginosa. However, its inappropriate continuation despite safer alternatives, as well as its discontinuation when no other options existed, raise concerns about antibiotic de-escalation practices. Interestingly, no significant differences in mortality or acute kidney injury were observed between patients who were treated with colistin and those who were not. These findings emphasize the need for antimicrobial stewardship programs and highlight the importance of large-scale trials to evaluate colistin\u2019s efficacy and safety in MDR infections.<\/jats:p>","DOI":"10.3390\/medicina61071275","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:45:52Z","timestamp":1752572752000},"page":"1275","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence, Appropriateness, and Outcomes of Colistin Use in Multidrug-Resistant Pseudomonas aeruginosa Infections: Insights from Hospital Data"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8298-4071","authenticated-orcid":false,"given":"Rana K.","family":"Abu-Farha","sequence":"first","affiliation":[{"name":"Clinical Pharmacy and Therapeutics Department, Faculty of Pharmacy, Applied Science Private University, Amman P.O. Box 11937, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savana","family":"Sobh","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Therapeutics Department, Faculty of Pharmacy, Applied Science Private University, Amman P.O. Box 11937, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawla","family":"Abu Hammour","sequence":"additional","affiliation":[{"name":"Department Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-9110","authenticated-orcid":false,"given":"Feras","family":"Darwish El-Hajji","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy and Therapeutics Department, Faculty of Pharmacy, Applied Science Private University, Amman P.O. Box 11937, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sireen A.","family":"Shilbayeh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4316-3224","authenticated-orcid":false,"given":"Rania","family":"Itani","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Department, Faculty of Pharmacy, Beirut Arab University, Beirut P.O. Box 11-5020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Aljeldah, M.M. (2022). Antimicrobial resistance and its spread is a global threat. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081082"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromsomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","first-page":"8","article-title":"Epidemiology of antibiotic resistance in Pseudomonas aeruginosa. Implications for empiric and definitive therapy","volume":"30","year":"2017","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00134-019-05905-6","article-title":"Understanding resistance in Pseudomonas","volume":"46","author":"Dimopoulos","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_6","unstructured":"WHO (2022). The WHO AWaRe (Access, Watch, Reserve) Antibiotic Book."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Talaat, M., Tolba, S., Abdou, E., Sarhan, M., Gomaa, M., and Hutin, Y.J.F. (2022). Over-prescription and overuse of antimicrobials in the Eastern Mediterranean Region: The urgent need for antimicrobial stewardship programs with access, watch, and reserve adoption. Antibiotics, 11.","DOI":"10.3390\/antibiotics11121773"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Abu Hammour, K., Al-Heyari, E., Allan, A., Versporten, A., Goossens, H., Abu Hammour, G., and Manaseer, Q. (2020). Antimicrobial consumption and resistance in a tertiary care hospital in Jordan: Results of an internet-based global point prevalence survey. Antibiotics, 9.","DOI":"10.3390\/antibiotics9090598"},{"key":"ref_9","unstructured":"Clinical and Laboratory Standards Institute (2011). Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1001312","DOI":"10.37349\/emed.2025.1001312","article-title":"Evaluation of empiric therapy appropriateness, resistance patterns, and mortality in Pseudomonas aeruginosa infections in Jordan","volume":"6","author":"Sobh","year":"2025","journal-title":"Explor. Med."},{"key":"ref_12","unstructured":"Wilson, M.G., and Pandey, S. (2023). Pseudomonas Aeruginosa, StatPearls."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JCM.01129-19","article-title":"Point-counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute recommendations for reporting antimicrobial susceptibility results","volume":"57","author":"Kahlmeter","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"dlab169","DOI":"10.1093\/jacamr\/dlab169","article-title":"Opportunities to enhance antibiotic stewardship: Colistin use and outcomes in a low-resource setting","volume":"3","author":"Moolla","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Trifi, A., Abdellatif, S., Abdennebi, C., Daly, F., Nasri, R., Touil, Y., and Ben Lakhal, S. (2018). Appropriateness of empiric antimicrobial therapy with imipenem\/colistin in severe septic patients: Observational cohort study. Ann. Clin. Microbiol. Antimicrob., 17.","DOI":"10.1186\/s12941-018-0292-7"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1183\/09031936.00156906","article-title":"Ventilator-associated pneumonia due to colistin susceptible-only microorganisms","volume":"30","author":"Rios","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_18","first-page":"EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2147\/IDR.S234211","article-title":"Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia","volume":"12","author":"Shi","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jgar.2019.06.009","article-title":"Use of colistin in adult patients: A cross-sectional study","volume":"20","author":"Giacobbe","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2014.03.001","article-title":"Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: A narrative review for the clinician","volume":"69","author":"Martis","year":"2014","journal-title":"J. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/647952","article-title":"Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices","volume":"49","author":"Reller","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","first-page":"148","article-title":"Effectiveness and safety of colistin in multi drug resistant urinary tract infections","volume":"7","author":"Karakkattu","year":"2017","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9111","DOI":"10.1007\/s13369-024-08830-z","article-title":"Effectiveness and Safety of Colistimethate Sodium Used in the Treatment of Neutropenic Blood Cancer Patients Infected with Multidrug-Resistant Pseudomonas aeruginosa","volume":"49","author":"Salman","year":"2024","journal-title":"Arab. J. Sci. Eng."},{"key":"ref_26","unstructured":"Knobler, S.L., Lemon, S.M., Najafi, M., and Burroughs, T. (2003). Factors Contributing to the Emergence of Resistance, National Academies Press."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ngoma, N., Perovic, O., de Voux, A., Musekiwa, A., Shuping, L., and GERMS-SA (2024). The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: A cross-sectional study. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09459-x"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1275\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:09:49Z","timestamp":1760033389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["medicina61071275"],"URL":"https:\/\/doi.org\/10.3390\/medicina61071275","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}